Optimizing Antiseizure Medication Taper in the Epilepsy Monitoring Unit

Clinical Snapshot

Key Findings

• P Value: Not reported in abstract

• Effect Size: Median ASM loads at seizure: 51% baseline (hBTCS), 41% (nBTCS), 39% (unclear group)

• Primary Outcome: ASM load at seizure occurrence and BTCS risk stratified by patient history

• Nnt Or Sensitivity: First seizures occurred at 33% baseline ASM load for both hBTCS and nBTCS groups

• Confidence Interval: Not reported in abstract

Clinical Application

Requires pharmacokinetic modeling capabilities and EMU infrastructure Relevant to Australian comprehensive epilepsy centers, though local validation needed. May inform TGA-approved ASM tapering protocols and support PBS-funded EMU admissions optimization Adult patients undergoing video-EEG monitoring in tertiary epilepsy centers

Abstract

BACKGROUND AND OBJECTIVES: Inpatient video-EEG epilepsy monitoring aims to provide a safe environment for antiseizure medication (ASM) tapering to precipitate seizures, which is often required for diagnosis and treatment. However, there is no standardized taper protocol across institutions, which may contribute to increased morbidity through longer hospitalizations if the taper is too mild and bilateral tonic-clonic seizures (BTCSs) if too aggressive. This study investigates how ASM taper influences length of stay (LOS) and patient outcomes in the epilepsy monitoring unit (EMU), aiming to develop guidelines for medication taper strategies to maximize diagnostic yield while minimizing patient risk. METHODS: We used natural language processing to extract data from electronic medical records of 639 patients admitted to the University of Pennsylvania EMU between 2017 and 2023. We estimated ASM load, the total normalized sum of all ASM serum concentrations based on dose-dependent pharmacokinetic models, throughout each hospitalization. We applied LASSO (Least Absolute Shrinkage and Selection Operator) regression and mixed-effects models to identify predictors of LOS and BTCS risk as a function of taper speed and percentage of baseline ASM load in patients with (hBTCS) and without (nBTCS) a history of BTCS. RESULTS: Taper speed did not correlate with BTCS risk, although absolute ASM load did. Median ASM loads at seizure occurrence were 51% of baseline in the hBTCS group, 41% in the nBTCS group, and 39% in the unclear group. BTCS occurred at higher ASM loads in patients with hBTCS vs nBTCS. Median ASM loads at first EMU seizure were 33% for both hBTCS and nBTCS groups, while the unclear group had first seizures at lower loads (25% of baseline). Time to first seizure and number of baseline ASMs were positively correlated with longer hospital stays, suggesting that sequential medication taper delayed seizures and prolonged LOS without altering BTCS risk. DISCUSSION: Patient history and ASM load are critical factors in predicting BTCS. Rapid taper to approximately 50% baseline ASM load may more efficiently produce seizures without increased BTCS risk in patients without BTCS history. Individualized taper protocols remain advised, particularly for severe epilepsies. This study provides a foundation for quantitative, evidence-based guidelines to optimize ASM reduction strategies for safely precipitating seizures in EMUs.

References

1. 1.Nix, K. C., Ghosn, N. J., Xie, K., Ojemann, W., Ellis, C. A., Waldman, G. J., Cornblath, E., Conrad, E., Ma, D., & Litt, B. (2026). Optimizing antiseizure medication taper in the epilepsy monitoring unit. Neurology Clinical Practice. https://doi.org/10.1212/CPJ.0000000000200606